Fig. 4

Mean cost of SAEs and SIs per 100 patients with UC treated with an advanced therapy. Dollar amounts represent the net combined costs for both SAEs and SIs. Bars to the left of $0 mark represent costs that are lower than those of the reference treatment vedolizumab. These lower costs for SIs partially offset the costs that are higher than those of the reference treatment to the right of the bar. BID twice daily, IV intravenous, PO by mouth, Q2W every 2 weeks, Q4W every 4 weeks, Q8W every 8 weeks, SAEs serious adverse events, SC subcutaneous, SIs serious infections, UC ulcerative colitis